Skip to content
PARK

Park Dental Partners, Inc. Common Stock

Park Dental Partners, Inc. Common Stock Q1 FY2026 earnings call

May 14, 2026 · fiscal period ended 2026-03

EPS · actual vs est

$0.44 / $0.19Beat +131.6%

Revenue · actual vs est

$62.7M / $61.0MBeat +2.8%
Ask about this call

Summary

Generated 2026-05-14

Management highlights

  • Core Business Performance

    • Q1 2026 results were in line with management expectations, consistent with the post-IPO growth plan, with solid 6.2% YoY total revenue growth and 4.1% same-practice revenue growth.
    • Growth was driven by increased patient visits, expanded clinical hours, and growth in the provider base; patient retention remains strong at just over 90%.
    • GAAP net loss for the quarter was $0.4 million ($0.09 loss per share), compared to net income of $1.6 million ($0.88 per share) in Q1 2025. Non-GAAP adjusted EBITDA was $4.7 million (7.6% of revenue), with adjusted EPS of $0.44 per share. Year-over-year earnings declines were driven by expected post-IPO share-based compensation and public company costs, partially offset by revenue growth and operating leverage.
    • The company ended the quarter with $24.4 million in cash, $11.5 million in total debt, and an undrawn $15 million revolving credit facility, providing strong financial flexibility for growth investments. Operating cash flow for the quarter was $5 million.
  • Growth Strategy

    • The company currently has 225 doctors across three states, with a strategy focused on building market density to unlock operating efficiencies, expand integrated specialty care, and strengthen brands.
    • M&A activity is disciplined, prioritizing cultural fit and long-term value creation over short-term metrics. One acquisition was completed in Q1 2026, with a healthy pipeline of aligned opportunities, though acquisition timing is hard to predict.
    • The company plans to continue growing in existing markets via adding providers to existing practices, selective acquisitions, and de novo openings, while entering 2-3 new markets over the next few years with a land-and-expand approach.
    • De novo practice development is expected to remain a smaller growth driver compared to M&A for the foreseeable future.
  • Culture and Governance

    • The company maintains a patient-first culture, keeps affiliated doctors at the center of governance and management, and prioritizes long-term value creation for shareholders.
    • Doctor shareholders account for approximately 91% of the company's share-based compensation expense. Pre-IPO share-based compensation is recognized via an accelerated method, so related expenses will decline over remaining quarters as they are fully recognized for GAAP purposes.
View in transcript ↓

Segment performance

Park Dental Partners operates two core practice segments. General practice generated revenue of $46.1 million in Q1 2026, representing 6.4% year-over-year growth, and contributed 73.5% of total company revenue. Multi-specialty practice generated revenue of $16.6 million in Q1 2026, representing 5.7% year-over-year growth, and contributed 26.5% of total company revenue. Total company revenue for the quarter was $62.7 million, a 6.2% increase year-over-year.

View in transcript ↓

Guidance

  • Management maintained its full year 2026 financial outlook, as Q1 results were fully in line with prior expectations and reflect solid underlying patient demand.
  • Quarterly revenue growth seasonality is expected for 2026: Q2 revenue growth is projected to be lower than Q1 2026, while Q3 and Q4 growth is expected to be at or above Q1's growth rate. This pattern is driven by seasonal hiring of new graduate doctors and hygienists, which typically peaks in summer, and the expected full integration of 2025 year-end and Q1 2026 acquisitions by the second half of 2026.
View in transcript ↓

Risks

  • Forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from projections; these risks are detailed in the company's recent earnings press release and SEC filings, and the company does not undertake to update forward-looking statements.
  • Acquisition timing is unpredictable, and the company will not sacrifice long-term strategic criteria to hit short-term growth metrics, which may lead to variable cadence of deal closing.
  • Management notes ongoing macroeconomic trends including higher inflation and energy prices, but has not observed any material shift in patient demand or visit volume to date, and continues to monitor these conditions.
View in transcript ↓

Q&A highlights

Q: How does the current acquisition pipeline compare to six months/one year ago, and have any deals been lost in 2026 to date?

A: Management reports the pipeline holds substantially more qualified opportunities across all practice sizes (solo, midsize, larger groups) than it did a year ago, with the team actively evaluating opportunities at various stages. No deals that met all of the company's strategic and cultural criteria have been lost in 2026, and the company's model is well-received by prospective sellers despite a competitive market.

Q: What are your plans for new graduate doctor hiring this summer, compared to last year?

A: The company maintains a strong pipeline of new graduate hires through university partnerships in its operating markets, and hiring activity is proceeding similarly to last year. While management did not confirm an exact hiring number, it expects the total provider count to continue increasing quarter over quarter, with normal seasonal variation in hiring timing, and provider growth is a key metric for the company's overall expansion.

Q: Have you observed any impact from broader macroeconomic pressures (higher inflation, energy prices) on patient demand for dental services?

A: Management has not seen any material change in patient behavior, patient visit volumes, or overall patient demand to date, and will continue monitoring macroeconomic trends moving forward.

Q: Is there an update on planned de novo practice openings, and how is the integration of the new Arizona market practices progressing?

A: The company does not disclose future de novo activity in advance and only announces locations after opening; M&A will remain the larger primary growth driver for the coming quarters, with de novo as a smaller secondary growth opportunity. Integration of the Arizona practices is proceeding smoothly, with conversion to the company's common practice management system scheduled to complete within a few weeks, and relationship building with the new local teams is progressing as planned.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$0.44$0.19+131.6%
Revenue$62.7M$61.0M+2.8%

Transcript

May 14, 2026

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.